Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

92.39 -0.93 (-1.00%)
Streaming Delayed Price Updated: 11:48 AM EST, Nov 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
74 75 Next >
News headline image
Got $5,000? These 3 Stocks Are Near Their 52-Week Lows and Are Underrated Buys ↗
These stocks all trade at less than 17 times their future expected earnings. 
Via The Motley Fool
News headline image
AstraZeneca Plc (AZN) Q4 2023 Earnings Call Transcript ↗
AZN earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
News headline image
Why Compass Minerals International Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Shares of Compass Minerals International, Inc. (NYSE: CMP) fell sharply during Thursday’s session following downbeat results. 
Via Benzinga
News headline image
Earnings Scheduled For February 8, 2024 ↗
Companies Reporting Before The Bell • Ares Management (NYSE:ARES) is expected to report quarterly earnings at $1.09 per share on revenue of $864.54 million. 
Via Benzinga
News headline image
Earnings Outlook For AstraZeneca ↗
 
Via Benzinga
News headline image
Check Out What Whales Are Doing With AZN ↗
 
Via Benzinga
News headline image
How Cytokinetics Overcame Two Setbacks And Doubled Its Stock Price Over A Month ↗
Cytokinetics is looking to take on Bristol Myers Squibb in treating a heart disease. 
Via Investor's Business Daily
News headline image
AstraZeneca Stock Tumbles After Q4 Performance - Here's Why ↗
AstraZeneca Q4 2023: $12.02 billion sales, 7% Y/Y growth, fueled by global demand for cancer drugs. Excluding COVID-19 meds, revenue rises 16%. CEO Soriot projects low double-digit growth in 2024. 
Via Benzinga
News headline image
AstraZeneca Downgraded On "Underwhelming" Q4 Earnings ↗
AZN stock took a header early Thursday after a mixed Q4 report and a downgrade to sell on "thoroughly underwhelming" results. 
Via Investor's Business Daily
News headline image
AstraZeneca Full year and Q4 2023 Financial Results
From AstraZeneca
Via Business Wire
News headline image
AstraZeneca expands US manufacturing footprint to accelerate ambitions in next-generation cell therapy discovery and development
From AstraZeneca
Via Business Wire
News headline image
NVO, LLY or AZN: Which Pharma Stock Is the Best Weight-Loss Investment? ↗
The relaunch of Wegovy last year caused a mad dash by weight loss stocks to compete for market leadership in anti-obesity drugs. 
Via InvestorPlace
News headline image
Markets suddenly price Eli Lilly stock for a breakout on earnings
The healthcare sector could see a sudden inflow of investment dollars, and Eli Lilly quickly becomes a favorite name in the space as markets and analysts bid up 
Via MarketBeat
Topics Bonds Economy
News headline image
History Says the Nasdaq Will Keep Soaring in 2024. Here's the Surprising Megacap Stock Wall Street Thinks Will Be the Biggest Winner. ↗
Hint: It's not Alphabet, Amazon, Apple, Meta Platforms, Microsoft, Nvidia, or Tesla. 
Via The Motley Fool
News headline image
Biden Administration To Send Pharma Companies Opening Offers For Medicare Program's First Ever Drug Price Negotiations ↗
The Inflation Reduction Act's impact on drug prices. Medicare challenges pharmaceutical costs, offering relief to seniors and addressing the soaring prices in the U.S. healthcare system. 
Via Benzinga
Topics Economy
News headline image
Take Your Ozempic: Why Late Entry Of Rival Weight-Loss Drugs Won't Floor Novo, Eli Shares ↗
Eli Lilly to report strong Q4 earnings thanks to successful diabetes treatments, while rivals like Novo Nordisk and Pfizer are also vying for a share of the weight-loss market. 
Via Benzinga
News headline image
3 No-Brainer Stocks to Buy With $500 Right Now ↗
A reasonably modest amount of money can go a long way when it's put to work in industry-leading businesses. 
Via The Motley Fool
News headline image
Medicare's Historic Negotiations To Lower Drug Prices, Analysts Anticipate Upto Potential Price Cuts Of 60% ↗
Explore the impact of the U.S. government's proposal on pharmaceuticals! Learn about Medicare's negotiation power, potential price cuts, and industry reactions. 
Via Benzinga
News headline image
Pfizer’s earnings growth trade at a deep discount, suddenly a buy
The healthcare sector is set to attract a new inflow of investment dollars, as seen in business activity and employment. Pfizer is the clear sector favorite 
Via MarketBeat
Topics Economy
News headline image
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with metastatic HER2-positive solid tumors
From AstraZeneca
Via Business Wire
News headline image
3 Magnificent Stocks to Buy and Hold Forever ↗
Many investors will want to consider owning these stocks for a long time. 
Via The Motley Fool
News headline image
Focus On Bristol Myers, Gilead Sciences, Johnson & Johnson, Novartis: FDA To Issue Classwide Black Box Warning on CAR-T Therapies For Blood Cancer Treatment ↗
In a significant development, the FDA is set to impose a classwide black box warning following its investigation into secondary T-cell cancers arising from the use of existing CAR-T therapies.  
Via Benzinga
News headline image
AIRSUPRA® (albuterol/budesonide) now available as the first and only FDA-approved anti-inflammatory rescue option for asthma
From AstraZeneca
Via Business Wire
News headline image
Week in Review: Lee’s Pharma Signs $138 Million Agreement For China Rights To Heart Failure Therapy ↗
Lee’s Pharma acquired China rights to a heart failure therapy from Windtree Therapeutics. Meanwhile, AstraZeneca signed an investment cooperation agreement with the Taizhou National Medical High-tech... 
Via Talk Markets
News headline image
AstraZeneca Tries To Reach New Ground For Its Lead Cancer Drug Imfinzi With New Data In Liver Cancer Study ↗
Explore results from AstraZeneca's EMERALD-1 Phase 3 trial on Imfinzi for unresectable hepatocellular carcinoma. Statistically significant improvement in progression-free survival with Imfinzi plus... 
Via Benzinga
News headline image
IMFINZI® (durvalumab) plus transarterial chemoembolization (TACE) and bevacizumab reduced the risk of disease progression or death by 23% vs. TACE in liver cancer eligible for embolization
From AstraZeneca
Via Business Wire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Are You Kidding Me? 3 Meme Stocks You Should Have Already Sold ↗
Be sure to sell these meme stocks as they represent fundamentally weak businesses that will continue to erode in value. 
Via InvestorPlace
News headline image
MarketBeat Week in Review – 1/8 - 1/12
Stocks drifted lower as the latest inflation numbers are dampening expectations for a rate cut; here are some of our top stories for your long weekend 
Via MarketBeat
Topics ETFs Economy
News headline image
Cytokinetics' Heart Drug Is A Multi-Billion Dollar Opportunity By 2032 Despite Novartis Setback: Analyst ↗
Novartis halts pursuit of Cytokinetics acquisition, impacting promising heart drug. Analysts estimate $3.6 billion sales for Cytokinetics' cardiomyopathy drug by 2032. Still lead drug aficamten viewed... 
Via Benzinga
< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
74 75 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.